Why the study?
How do plasma antithrombin III levels and kaolin-activated partial thromboplastin time vary across different stages of ischemic heart disease risk and acute myocardial infarction?
How do plasma antithrombin III levels and kaolin-activated partial thromboplastin time vary across different stages of ischemic heart disease risk and acute myocardial infarction?
Plasma antithrombin III levels increase progressively with ischemic heart disease risk and peak during acute myocardial infarction, suggesting a gradual failure of coagulation damping mechanisms.
Answers are grounded in this paper and cite their sources.
May reflect compensatory antithrombin changes across IHD stages but should not change practice; leaves open predictive utility in prospective cohorts.
The amount of antithrombin III in plasma was determined quantitatively in 218 males between 45-60 years of age. The mean antithrombin III value was found to be low in the group with low risk for ischemic heart disease, intermediate in the group with high risk for ischemic heart disease and highest in the group with acute myocardial infarction. Concomitant study of kaolin-activated partial thromboplastin time revealed a sharp decrease in its mean value in the group with acute myocardial infarction. The high correlation between antithrombin III and kaolin-activated partial thromboplastin time for the entire population suggests that the development of ischemic heart disease is a gradual process and that failure of the damping mechanism results as an acute event. These findings may be useful in the determination of the coagulation state of these patients.
No takes yet. Share an insight, caveat, or question.
Yue et al. (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: